BioCentury | Apr 20, 2017
Product R&D

Stalling translation

...of PCSK9 in preclinical development that were out-licensed to an undisclosed company last year, and Liphorus Pharmaceuticals Inc....
...NASDAQ:AMGN), Thousand Oaks, Calif. Arrakis Therapeutics Inc., Waltham, Mass. Genentech Inc., South San Francisco, Calif. Liphorus Pharmaceuticals Inc....
BioCentury | Oct 5, 2015
Emerging Company Profile

Picking a PCSK9

...are making their market debuts, several companies are vying to replace them with oral candidates. Liphorus Pharmaceuticals Inc....
...Genentech Inc., South San Francisco, Calif. Institut de Recherches Cliniques de Montréal (IRCM), Montreal, Quebec Liphorus Pharmaceuticals Inc....
..."Nurturing killer seeds." BioCentury (2014) Martz, L. "PCSK9 peptide inhibitors." SciBX: Science-Business eXchange (2014) Sidebars Liphorus Pharmaceuticals Inc....
BioCentury | Sep 21, 2015
Product Development

Alnylam's lipid sync

...ALN-PCSsc's dosing also could improve adherence over oral approaches to inhibiting PCSK9. Pfizer Inc. , Liphorus Pharmaceuticals Inc....
...Mass. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. European Society of Cardiology (ESC), Sophia Antipolis, France Liphorus Pharmaceuticals Inc....
BioCentury | Nov 10, 2014
Company News

IRCM, Liphorus Pharmaceuticals deal

...financial terms are not disclosed. Institut de Recherches Cliniques de Montreal (IRCM) , Montreal, Quebec Liphorus Pharmaceuticals Inc....
BioCentury | Nov 7, 2014
Financial News

Sanderling backs IRCM spinout Liphorus

Liphorus Pharmaceuticals Inc. (Montreal, Quebec) raised $6.4 million in a series A round from Sanderling Ventures. The startup plans to develop small molecules targeting proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) to treat hypercholesterolemia. The company...
Items per page:
1 - 5 of 5
BioCentury | Apr 20, 2017
Product R&D

Stalling translation

...of PCSK9 in preclinical development that were out-licensed to an undisclosed company last year, and Liphorus Pharmaceuticals Inc....
...NASDAQ:AMGN), Thousand Oaks, Calif. Arrakis Therapeutics Inc., Waltham, Mass. Genentech Inc., South San Francisco, Calif. Liphorus Pharmaceuticals Inc....
BioCentury | Oct 5, 2015
Emerging Company Profile

Picking a PCSK9

...are making their market debuts, several companies are vying to replace them with oral candidates. Liphorus Pharmaceuticals Inc....
...Genentech Inc., South San Francisco, Calif. Institut de Recherches Cliniques de Montréal (IRCM), Montreal, Quebec Liphorus Pharmaceuticals Inc....
..."Nurturing killer seeds." BioCentury (2014) Martz, L. "PCSK9 peptide inhibitors." SciBX: Science-Business eXchange (2014) Sidebars Liphorus Pharmaceuticals Inc....
BioCentury | Sep 21, 2015
Product Development

Alnylam's lipid sync

...ALN-PCSsc's dosing also could improve adherence over oral approaches to inhibiting PCSK9. Pfizer Inc. , Liphorus Pharmaceuticals Inc....
...Mass. Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. European Society of Cardiology (ESC), Sophia Antipolis, France Liphorus Pharmaceuticals Inc....
BioCentury | Nov 10, 2014
Company News

IRCM, Liphorus Pharmaceuticals deal

...financial terms are not disclosed. Institut de Recherches Cliniques de Montreal (IRCM) , Montreal, Quebec Liphorus Pharmaceuticals Inc....
BioCentury | Nov 7, 2014
Financial News

Sanderling backs IRCM spinout Liphorus

Liphorus Pharmaceuticals Inc. (Montreal, Quebec) raised $6.4 million in a series A round from Sanderling Ventures. The startup plans to develop small molecules targeting proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) to treat hypercholesterolemia. The company...
Items per page:
1 - 5 of 5